Nagoya University · Faculty of Medicine / Graduate School of Medical Sciences

Research keywordsnon-small cell lung cancer・immune checkpoint inhibitors・PD-1 PD-L1 inhibitors・radiomics survival prediction・oncogenic driver mutations・lorlatinib response・bronchoscopy simulation・transbronchial cryobiopsy・docetaxel ramucirumab・interstitial lung disease

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors2026 · Respiratory Investigation 64 巻 ( 2 ) 頁： 101383 2026年3月
• Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer2026 · Journal of Chemotherapy 38 巻 ( 2 ) 頁： 177 - 186 2026年
• Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer2024 · BMC Cancer 24 巻 ( 1 ) 頁： 1417 2024年12月
• Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report2024 · CASE REPORTS IN ONCOLOGY 17 巻 ( 1 ) 頁： 942 - 949 2024年

• Official profile